Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCT800 Prophylaxis in Severe Hemophilia A
NCT03815318Phase 3Completed
- Sponsor
- Sinocelltech Group Limited
- Start
- Jan 2019
- Primary completion
- Jan 2020
- Modality
- Biologic, rProtein (Recombinant Protein)
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of omfiloctocog alfa in hemophilia A, sponsored by Sinocelltech Group Limited. Primary endpoint: Annualized Bleeding Rate at 24 weeks. Started Jan 2019; status: completed.
02
Drugs
omfiloctocog alfa
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NCT03815318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03815318.